The collaboration aims to advance the performance of cell-based ion channel assays in screening applications.
“We are pleased that AstraZeneca sees the value of our microfluidic-based solutions for drug discovery,” said Dr Mattias Karlsson, VP of R&D at Cellectricon. “The fantastic market acceptance of Dynaflow, our first generation of microfluidic-based tools supports the unique possibilities the micro-scale format offers such as superior performance characteristics and robustness.”
In other AstraZeneca related news, the FDA recently approved an expanded indication for the company’s gastroesophageal reflux disease treatment Nexium. The drug, previously only approved for adults, will now be available to treat US teenagers between the ages of 12 and 17.